- Home
- ASC vs ALT Comparison
ASC vs ALT Comparison
Compare ASC & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASC | ALT |
|---|---|---|
| Founded | 2010 | 1997 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 497.7M | 501.9M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | ASC | ALT |
|---|---|---|
| Price | $11.82 | $5.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $13.67 | ★ $16.33 |
| AVG Volume (30 Days) | 607.3K | ★ 3.3M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 7.99% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $309,326,000.00 | $20,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.36 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.32 | $2.90 |
| 52 Week High | $13.85 | $10.11 |
Technical Indicators
Market Signals| Indicator | ASC | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 40.05 | 66.17 |
| Support Level | $11.75 | $4.70 |
| Resistance Level | $12.41 | $5.46 |
| Average True Range (ATR) | 0.44 | 0.33 |
| MACD | -0.13 | 0.04 |
| Stochastic Oscillator | 3.04 | 84.53 |
Price Performance
Historical ComparisonAbout ASC Ardmore Shipping Corporation
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The Company operates its business in one operating segment, the transportation of refined petroleum products and chemicals.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.